RenovoRx Appoints Richard A. Stark to Board
The medical device company added the former Innoblative Designs CEO, who has advised it since late 2024, to its board of directors.
Updated on Nov. 19, 2026 in Business

RenovoRx has appointed Richard A. Stark to its Board of Directors, announced in a GLOBE NEWSWIRE press release datelined Mountain View, Calif. Stark is Chief Executive Officer of Innoblative Designs, Inc. and has advised RenovoRx since late 2024.
Why it matters
The appointment brings more than three decades of medical technology leadership to the board as RenovoRx works toward commercial growth. The company says Stark has been instrumental in building commercial infrastructure that is accelerating physician adoption of its RenovoCath product.
Stark brings more than three decades of medical technology leadership experience to the RenovoRx board. The source does not state any financial figures tied to the appointment.
The players
RenovoRx
RenovoRx is a clinical-stage company developing RenovoCath, a drug-delivery technology for pancreatic cancer and related cancers.
Richard A. Stark
Richard A. Stark is a medical technology executive and CEO of Innoblative Designs, Inc. who has served as an independent director of several medical technology companies.
The details
Stark, who is CEO of Innoblative Designs, Inc., is also founder and principal of RAS Consulting Firm, LLC and founder and managing member of MedTech Angels. He serves as an independent director of Pleural Dynamics and Polyembo.
Timeline
Late 2024: Stark begins advising the RenovoRx commercial team.
August 2026: RenovoRx completes enrollment in the Phase III TIGeR-PaC clinical trial.
November 19, 2026: Stark's board appointment is announced.
Second half of 2027: RenovoRx anticipates initial topline TIGeR-PaC trial data.
Market Landscape
The appointment follows RenovoRx's completion of enrollment in the Phase III TIGeR-PaC trial, the company's pivotal study in pancreatic cancer. The company's regulatory path also includes Orphan Drug Designation for RenovoCath with gemcitabine and oxaliplatin for pancreatic cancer.
For investors and patients following RenovoRx, the board addition signals added commercial experience ahead of the TIGeR-PaC readout. The source does not describe any direct change to product availability or pricing.
The takeaway
Watch for the TIGeR-PaC topline data expected in the second half of 2027, which will be the next major test of RenovoCath's clinical case.
What happens next
RenovoRx anticipates initial topline data from the Phase III TIGeR-PaC trial in the second half of 2027.
Further reading
Explore more People coverage from Mountain View business news.
Source note: This article includes information reported by The Manila times.






